Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: a systematic review
AS Komorowski, HJ MacKay, RC Pezo - Cancer Medicine, 2020 - Wiley Online Library
Background Clinical trial reports often emphasize efficacy over harms, leading to
misinterpretation of the risk‐to‐benefit ratio of new therapies. Clear and sufficiently detailed …
misinterpretation of the risk‐to‐benefit ratio of new therapies. Clear and sufficiently detailed …
[HTML][HTML] Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review
AS Komorowski, HJ MacKay, RC Pezo - Cancer Medicine, 2020 - ncbi.nlm.nih.gov
Background Clinical trial reports often emphasize efficacy over harms, leading to
misinterpretation of the risk‐to‐benefit ratio of new therapies. Clear and sufficiently detailed …
misinterpretation of the risk‐to‐benefit ratio of new therapies. Clear and sufficiently detailed …
Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review.
AS Komorowski, HJ MacKay, RC Pezo - Cancer Medicine, 2020 - search.ebscohost.com
Background: Clinical trial reports often emphasize efficacy over harms, leading to
misinterpretation of the risk‐to‐benefit ratio of new therapies. Clear and sufficiently detailed …
misinterpretation of the risk‐to‐benefit ratio of new therapies. Clear and sufficiently detailed …
[PDF][PDF] Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic
AS Komorowski, HJ MacKay, RC Pezo - 2020 - researchgate.net
Background: Clinical trial reports often emphasize efficacy over harms, leading to
misinterpretation of the risk-to-benefit ratio of new therapies. Clear and sufficiently detailed …
misinterpretation of the risk-to-benefit ratio of new therapies. Clear and sufficiently detailed …
Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review.
AS Komorowski, HJ MacKay, RC Pezo - Cancer Medicine, 2020 - europepmc.org
Background Clinical trial reports often emphasize efficacy over harms, leading to
misinterpretation of the risk-to-benefit ratio of new therapies. Clear and sufficiently detailed …
misinterpretation of the risk-to-benefit ratio of new therapies. Clear and sufficiently detailed …
Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review
AS Komorowski, HJ Mackay, RC Pezo - Cancer Medicine, 2020 - hero.epa.gov
Background Clinical trial reports often emphasize efficacy over harms, leading to
misinterpretation of the risk-to-benefit ratio of new therapies. Clear and sufficiently detailed …
misinterpretation of the risk-to-benefit ratio of new therapies. Clear and sufficiently detailed …
Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review
AS Komorowski, HJ MacKay, RC Pezo - Cancer Medicine, 2020 - search.proquest.com
Background Clinical trial reports often emphasize efficacy over harms, leading to
misinterpretation of the risk‐to‐benefit ratio of new therapies. Clear and sufficiently detailed …
misinterpretation of the risk‐to‐benefit ratio of new therapies. Clear and sufficiently detailed …
Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review
AS Komorowski, HJ MacKay, RC Pezo - Cancer medicine, 2020 - pubmed.ncbi.nlm.nih.gov
Background Clinical trial reports often emphasize efficacy over harms, leading to
misinterpretation of the risk-to-benefit ratio of new therapies. Clear and sufficiently detailed …
misinterpretation of the risk-to-benefit ratio of new therapies. Clear and sufficiently detailed …